Shikonin regulates HeLa cell death via caspase-3 activation and blockage of DNA synthesis by Wu, Z. et al.
This article was downloaded by: [The University Of Melbourne Libraries]
On: 21 January 2015, At: 21:55
Publisher: Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House,
37-41 Mortimer Street, London W1T 3JH, UK
Journal of Asian Natural Products Research
Publication details, including instructions for authors and subscription information:
http://www.tandfonline.com/loi/ganp20
Shikonin regulates HeLa cell death via caspase-3
activation and blockage of DNA synthesis
Zhen Wu b , Li-Jun Wu c , Lin-Hao Li b , Shin-Ichi Tashiro d , Satoshi Onodera d & Takashi
Ikejima b
a Department of Pharmaceutical Science , Heilongjiang University , 150080, Harbin, China
b China-Japan Research Institute of Medical and Pharmaceutical Sciences , Shenyang
Pharmaceutical University , 103 Wenhua Road, 110016, Shenyang, China
c Department of Phytochemistry , Shenyang Pharmaceutical University , 110016, Shenyang,
China
d Department of Clinical and Biomedical Sciences , Showa Pharmaceutical University ,
Machida, 194-8543, Tokyo, Japan
Published online: 22 Aug 2006.
To cite this article: Zhen Wu , Li-Jun Wu , Lin-Hao Li , Shin-Ichi Tashiro , Satoshi Onodera & Takashi Ikejima (2004) Shikonin
regulates HeLa cell death via caspase-3 activation and blockage of DNA synthesis, Journal of Asian Natural Products Research,
6:3, 155-166, DOI: 10.1080/1028602032000169622
To link to this article:  http://dx.doi.org/10.1080/1028602032000169622
PLEASE SCROLL DOWN FOR ARTICLE
Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained
in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no
representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the
Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and
are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and
should be independently verified with primary sources of information. Taylor and Francis shall not be liable for
any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever
or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of
the Content.
This article may be used for research, teaching, and private study purposes. Any substantial or systematic
reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any
form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://
www.tandfonline.com/page/terms-and-conditions
SHIKONIN REGULATES HELA CELL DEATH VIA
CASPASE-3 ACTIVATION AND BLOCKAGE OF DNA
SYNTHESIS
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Pharmaceutical University, Shenyang 110016, China; dDepartment of Clinical and Biomedical
Sciences, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan
(Received 17 July 2003; Revised 24 September 2003; In final form 7 October 2003)
Shikonin, isolated from the plant Lithospermum erythrorhizon Sieb. Et Zucc, inhibited tumor cell growth and
induced cell death in various tumor cells, with 50% growth inhibition of human cervical cancer cells, HeLa, at
18:9 ^ 1:1mmol L21: Treated with 40mmol L21 shikonin, HeLa cells underwent marked apoptotic morphological
changes such as a round shape, membrane blebbing and apoptotic bodies derived from the fragmented nuclei.
Another hallmark of apoptosis, DNA fragmentation, was observed by gel electrophoresis. Shikonin (10mmol L21)
significantly blocked the transition from G1 to S phase in the HeLa cell cycle. Pan-caspase inhibitor (Z-VAD-FMK),
caspase-3 inhibitor (Z-DEVD-FMK) or caspase-8 inhibitor (Z-IETD-FMK) effectively inhibited shikonin-induced
cell death, while caspase-1 inhibitor (Ac-YVAD-CMK) and caspase-9 inhibitor (Z-LEHD-FMK) failed to affect cell
death. Caspase-3 activity significantly increased within 12 h after shikonin treatment. Reduced expression of
inhibitor of caspase-activated deoxyribonuclease (ICAD) after exposure to shikonin for 12 h suggests the resultant
activation of caspase-activated deoxyribonuclease (CAD), leading to apoptosis.
Keywords: Shikonin; Apoptosis; HeLa cells; Caspases
INTRODUCTION
Shikonin (Fig. 1) is a naphthoquinone that has been isolated from the ground rhizome of
Lithospermum erythrorhizon Sieb. Et Zucc, which has been used as herbal medicine in
East Asia [1]. Shikonin has anti-inflammatory [2,3], antifungal [4], antitumor effects and
inhibits angiogenesis in vivo and in vitro [5,6]. It has been also reported that shikonin
derivatives inhibit DNA topoisomerases and induce human premyelocytic leukemia HL60
cell apoptosis [7–9]. Topoisomerase inhibitors, widely used in cancer therapy, induce
apoptosis in various tumor cells. Etoposide, a topoisomerase II inhibitor, induced apoptosis
in HL60 cells [10].
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Apoptosis, or programmed cell death, is an important process in biological systems,
including normal cell turnover, immune system, embryonic development, metamorphosis and
endocrine-dependent tissue atrophy. Apoptosis is characterized by a decrease in cell volume,
condensation and fragmentation of nuclear chromatin and dilatation of the endoplasmic
reticulum. The cells undergoing apoptosis execute the death program by activating caspases.
Caspases, a family of at least 14 related cysteine proteases, are mediators of apoptotic
processes caused by various inducers such as Fas ligand, TNFa, etoposide and actinomycin D
[11]. Caspase-3 plays a crucial role in the apoptotic progression. As an executor it is activated
from an inactive precursor by upstream caspases, and activated caspase-3 then cleaves ICAD,
leading to activation of a latent cytosolic endonuclease, CAD, which cleaves DNA into
oligonucleosomal fragments, a hallmark of apoptotic cell death [12,13].
Recently, many natural products have been reported to exert their antitumor effects
through various apoptotic pathways [14,15]. In the present study, human cervical epithelial
cancer cells, HeLa, were used to examine the molecular mechanisms involved in the
apoptotic signal transduction pathways.
RESULTS AND DISCUSSION
Inhibition of Cell Growth by Shikonin
Inhibitory effects of shikonin on the growth of four tumor cell lines were detected by MTT
assay. The IC50 for A375-S2 cells, MCF-7 cells and L929 cells were 7:1 ^ 0:9; 22:1 ^ 2:5
and 14:5 ^ 1:2mmol L21; respectively (Table I). Shikonin (2.5–80mmol L21) induced
HeLa cell death in a time- and dose-dependent manner, as measured by MTT assay. The IC50
of a 48 h time course was 18:9 ^ 1:1mmol L21 (Fig. 2).
FIGURE 1 Structure of shikonin.
TABLE I Inhibitory effects of shikonin on the growth of various tumor cellsa
Cell lines IC50 (mmol L
21)
HeLa 18.9 ^ 1.1
A375-S2 7.1 ^ 0.9
MCF-7 22.1 ^ 2.5
L929 14.5 ^ 1.2
a Cells were incubated with shikonin for 48 h. Percentage viability was determined by the MTT assay. Each result represents three
independent experiments.










































Shikonin Induces Apoptotic Cell Death in HeLa Cells
To determine whether the features of HeLa cell death induced by shikonin were caused
by apoptosis or necrosis, cellular morphology and DNA fragmentation were examined.
The cells underwent marked morphological changes (Fig. 3A, right) upon treatment with
40mmol L21 shikonin compared with the untreated control (Fig. 3A, left). The HeLa cells
became round, and granular apoptotic bodies were observed. Hoechst 33258-stained HeLa
cells showed that the apoptotic cells had characteristic condensed nuclei (Fig. 3B, right).
FIGURE 2 Inhibitory effects of shikonin on the growth of HeLa cells. HeLa cells were treated with various
concentrations of shikonin. Treatment of HeLa cells with cisplatin for 24 h was used as positive control. The viability
was determined by the MTT assay. Data are presented as the mean ^ SD of the results for three independent
experiments.
FIGURE 3 Shikonin-induced apoptosis in HeLa cells. (A) Morphological changes of HeLa cells treated with
shikonin were observed in the absence (left) and presence (right) of shikonin (40mmol L21) at 24 h with £ 200
magnification. Arrows indicate multiblebbing cells and apoptotic bodies. (B) Morphological changes of HeLa cell
nuclei were observed by fluorescence microscopy (left) medium control (right) treated with shikonin (40mmol L21)
for 24 h. Cells were stained with Hoechst 33258 to identify apoptotic cells with £ 400 magnification; arrows indicate
fragmented nuclei.










































Treatment with 20 and 40mmol L21 shikonin for 24 h resulted in typical DNA fragmentation
in agarose electrophoresis, a hallmark of apoptosis (Fig. 4). These results demonstrated that
the cause of some HeLa cell death induced by shikonin was apoptosis.
Cell death induced by various stimuli occurs by either of two distinct mechanisms,
necrosis or apoptosis. There are some reports that both modes of cell death can be found in the
same cell [16]. The ratio of LDH released from viable cells, floating dead cells and the culture
medium was used to distinguish the number of apoptotic and necrotic cells. After exposure to
40mmol L21 shikonin for 24 h, the proportion of apoptotic cells reached a maximum
(54.37%) at 24 h, then started to decline, whereas the proportion of necrotic cells increased
time dependently (Fig. 5A). Higher doses (80mmol L21) of shikonin caused earlier induction
of necrosis, compared with the lower dose (Fig. 5B). These results indicate that, in early
stages, the major cause of HeLa cell death was apoptosis; however, after 48 h, necrosis plays
a greater part in the cell death.
Flow cytometric analysis of 40mmol L21 shikonin-treated HeLa cells showed that ratio of
the apoptotic DNA fragmentation increased in a time-dependent manner (Fig. 6).
Effects of Shikonin on the Cell Cycle
Some natural products reportedly induced cell cycle arrest and apoptosis. The alcohol extract
of Ganoderma lucidum can inhibit cell growth by preventing the transition from G1 to S
phase in HeLa cells and induce cell cycle arrest at the G1 phase in MCF-7 human breast
cancer cells [17,18]. Tetrandrine induced cell cycle arrest at the G1 phase and apoptosis in
A549 human lung carcinoma cells, which was associated with the induction of p21 [19].
When HeLa cells were treated with 2.5 mmol L21 thymidine (an agent that blocks cell cycle
transition from G1 to S phase), the cells were effectively blocked at the G1 phase (Fig. 7a).
After further treatment with 0, 0.1, 1 and 10mmol L21 shikonin for 12 h, the numbers of
G2/M phase cells were detected by fluorescence flow cytometry. 10mmol L21 shikonin
FIGURE 4 Internucleosomal DNA fragmentation induced in HeLa cells by shikonin. HeLa cells were treated with
shikonin for 24 h (lane A, marker, and lane B, 0; lane C, 20; lane D, 40mmol L21).










































significantly blocked the transition from G1 to S and S to G2/M phase (Fig. 7e). The
proportion of cells in G2/M was 12.22% compared with 55.33% of the shikonin-free culture
(Fig. 7b). However, cell cycle blockage was not observed in HeLa cells treated with lower
FIGURE 6 Effects of shikonin on the induction of apoptosis by DNA damage in HeLa cells. HeLa cells (1 £ 106
cells) were treated with shikonin (40mmol L21) and the DNA content after PI staining was analyzed by fluorescence
flow cytometry.
FIGURE 5 Characterization of cell death induced by shikonin in HeLa cells. HeLa cells were treated with (A) 40
and (B) 80mmol L21 shikonin. The extent of cell death was assessed by LDH activity-based assays. Data are the
mean ^ SD of the results for three independent experiments.










































doses (0.1 and 1mmol L21) of shikonin (Fig. 7c,d). It is suggested that shikonin induced
HeLa cell apoptosis by blocking the DNA synthesis.
Effects of Caspase Inhibitors on Shikonin-induced Cell Death
To assess the participation of caspases in the shikonin-induced cell death, five caspase
inhibitors were applied. Shikonin-induced apoptosis was blocked by pan-caspase
inhibitor (20mmol L21, Z-VAD-FMK), indicating that caspase family proteinases play a
role in shikonin-induced HeLa cell apoptosis. Caspase-3 inhibitor (20mmol L21)
FIGURE 7 Effects of shikonin on the cell cycle. After treatment with 2.5 mmol L21 thymidine (a), HeLa cells were
further untreated (b) and treated with 0.1 (c), 1 (d) and 10mmol L21 (e) shikonin for 12 h. Cells were washed with
PBS and stained with PI followed by flow cytometric analysis. Arrows indicate cells at the G2/M phase. Cells were
blocked at the G1 phase after thymidine treatment (a).










































(Z-DEVD-FMK) and caspase-8 inhibitor (20mmol L21) (Z-IETD-FMK) significantly
reversed 40mmol L21 shikonin-induced cell death, whereas caspase-1 inhibitor (Ac-
YVAD-CMK) at any doses failed to inhibit cell death (Fig. 8). These results indicate
participation of capase-8 activity in shikonin-induced HeLa cell death. It was reported
that activation of c-myc led caspase-8 to participate in the mitochondrial pathway, which
amplified the caspase-8-dependent receptor-interacting protein (RIP) death signal [20].
Therefore, the effects of caspase-9 inhibitor on shikonin-induced HeLa cell death were
examined. Three doses of caspase-9 inhibitor (5, 10 and 20mmol L21), Z-LEHD-
FMK, failed to reverse the shikonin-induced cell death. Unexpectedly, a high dose of
caspase-9 inhibitor rendered the cells even more sensitive to shikonin and the high
dose of caspase-1 inhibitor also tended to weakly augment the cell death (Fig. 8).
This sensitization might be correlated to a higher production of reactive oxygen radicals
[21]. To further confirm that the Apaf-1/caspase-9 apoptosome was not involved in this
death pathway, we examined the expression of cytochrome c protein by Western blotting
assay. However, cytochrome c was not released to cytosol from mitochondria in the
apoptotic progression (data not shown). These results suggest that shikonin might induce
HeLa cell death via caspase-9-independent pathways, and apoptotic synergy between
c-myc and caspase-8 pathway was not involved in this pathway.
Shikonin Triggers the Activation of Caspase-3 and Caspase-8 in HeLa Cells
To confirm the involvement of caspases in shikonin-induced HeLa cells apoptosis, the
activities of caspase-3 and caspase-8 proteinases were measured. Upon treatment of HeLa
cells with 40mmol L21 shikonin, caspase-3 activity increased markedly within 12 h after
the drug treatment (about 4.4 times that of the control), then continued to reach 6.3 times the
control level at 24 h (Fig. 9). Simultaneously, the shikonin-treated HeLa cells underwent
relative activation of upstream caspase-8 (about 1.4–2.4 times to the control). This signal
transduction pathway resembled the Fas and TNF pathways. Activation of caspase-8 might
be mediated by several death receptors including Fas, a plausible mechanism in which the
expression of Fas-L would be induced by shikonin in HeLa cells. However, our preliminary
FIGURE 8 Effects of various caspase inhibitors on shikonin-induced HeLa cell death. HeLa cells (1 £ 104 cells)
were pretreated with Z-VAD-FMK, Z-DEVD-FMK, Z-IETD-FMK, Ac-YVAD-CMK and Z-LEHD-FMK for 1 h and
then treated with shikonin (40mmol L21) for 24 h. Data are presented as the mean ^ SD of the results for three
independent experiments (n ¼ 3; p , 0:05; p , 0:01 vs. shikonin alone group).










































data showed the effect of shikonin-induced apoptotic HeLa cell death was not decreased in
the presence of competitive antagonistic anti-Fas antibody (data not shown).
Shikonin-induced ICAD Expression in HeLa Cells
To further examine the role of downstream caspase-3 in shikonin-induced HeLa cells
apoptosis, we performed Western blot analysis to examine ICAD expression during cell
death. ICAD was expressed as two isoforms, a Mr 45,000 isoform (ICAD-L/DFF45) and a Mr
35,000 isoform (ICAD-S/DFF35). ICAD-L/DFF45 was reported to be functional because
can act as a molecular chaperone for the nuclease to ensure its correct folding [22].
The activation of CAD is attributed to the cleavage of ICAD, which is specifically cleaved by
caspase-3 or -7 [14]. Caspase-3 or -7 initiated apoptotic DNA fragmentation by proteolytical
inactivation of ICAD, resulting in the release of active CAD [13]. Exposure of HeLa cells to
shikonin for 12 h reduced the expression of inactivating ICAD; this decline was effectively
prevented by caspase-3 inhibitor (Z-DEVD-FMK) after 24 h (Fig. 10). Thus, these
experiments provide additional evidence of caspase-3 activation in the shikonin-induced
apoptotic pathways in HeLa cells.
Pan-caspase inhibitor Z-VAD-FMK, casepase-3 inhibitor Z-DEVD-FMK and caspase-8
inhibitor Z-IETD-FMK did not completely inhibit shikonin-induced HeLa cell death.
Consequently, an unknown apoptotic pathways might participate in shikonin-induced HeLa
cell death.
FIGURE 9 Activities of caspase proteases during apoptosis induced by shikonin. HeLa cells (1 £ 106 cells) were
incubated with or without shikonin (40mmol L21). Caspase-3 (square) and caspase-8 (circle) activities (units per mg
of protein) were measured. Data are presented as the mean ^ SD of the results for three independent experiments
(n ¼ 3; p , 0:05 vs. without shikonin group).
FIGURE 10 Effects of shikonin on the expression of ICAD. Western blotting analysis for ICAD protein expression
in HeLa cells treated with shikonin (40mmol L21) for various time periods.










































In conclusion, shikonin, in part, activated caspase-8 in HeLa cells, which triggers
mitochondrial pathway-independent caspase cascades, leading to activation of caspase-3 and
DNA fragmentation, simultaneously, which blocked the G1 to S transition.
EXPERIMENTAL
Chemicals
Shikonin was obtained from the Beijing Institute of Biologic Products (Beijing, China).
The caspase-8 apoptosis detection kit, caspase-3 apoptosis detection kit and polyclonal rabbit
antibodies to human ICAD for Western blot analysis were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Ac-Val-Ala-Asp-CMK (Ac-YVAD-CMK), Z-Ile-Glu
(OMe)-Thr-Asp (Ome)-FMK (Z-IETD-FMK), Z-LEHD-FMK were purchased from Enzyme
Systems (CA, USA). Benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone (Z-DEVD-
FMK) and benzyloxy-carbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD-FMK) were
purchased from Calbiochem (CA, USA). Hoechst 33258, propidium iodide (PI), RNase A,
proteinase K and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were
purchased from Sigma Chemicals (St. Louis, MO). An antagonistic anti-Fas antibody (UB2)
was obtained from the Medical & Biological Laboratories (Osaka, Japan). Cisplatin was
purchased from the Jinzhou Pharmaceutical Factory (Jinzhou, China).
Cell Lines and Cell Culture
Human cervical cancer cells (HeLa #CCL-2), human malignant melanoma cells (A375-S2
#CRL-1872) and mouse fibrosarcoma cells (L929 #CRL-2148) were obtained from the
American Type Culture Collection (ATCC Manassas, VA). The cells were cultured in RPMI
1640 (GIBCO, USA) supplemented with 10% fetal bovine serum (Dalian Biological Reagent
Factory, Dalian, China), L-glutamine (2 mmol L21, GIBCO), penicillin (100 U mL21) and
streptomycin (100mg mL21) and maintained at 378C with 4% CO2 in a humidified
atmosphere.
Cytotoxicity Assay
The cytotoxic effect of shikonin on HeLa cells was measured by MTT assay as described
previously [23]. The cells were dispensed in 96-well flat bottom microtiter plates (NUNC,
Roskilde, Denmark) at a density of 1 £ 104 cells per well. After 12 h incubation, they were
treated with various concentrations of shikonin for the indicated time periods. The cells
were incubated with inhibitors for 1 h prior to the administration of shikonin. Cell growth
was measured with an ELISA reader (TECAN SPECTRA, Wetzlar, Germany) by MTT assay
at the indicated time points.
Cell death ð%Þ ¼ ðA490;control 2 A490;shikoninÞ=A490;control £ 100%
Morphological Changes
HeLa cells were placed in the wells of a six-well plate. After 12 h cell culture they were
treated with shikonin for the indicated time periods. The cellular morphology was observed
by means of photomicroscopy (Motic Incorporation Ltd, Hong Kong). After cells were
treated with shikonin, they were washed by PBS and fixed in 3.7% formaldehyde overnight.










































The cells were centrifuged and washed, then stained with Hoechst 33258. Apoptotic cells
were identified as cells with condensed and fragmented nuclei.
DNA Fragmentation Assay
HeLa cells (1 £ 106 cells) were collected by centrifugation at 150g for 5 min, and washed
with Ca2þ- and Mg2þ-free phosphate buffered saline (PBS). The cells were pelleted and
suspended in 10 mmol L21 Tris (pH 7.4), 10 mmolmmol L21 EDTA (pH 8.0), 0.5% Triton
X-100 and kept at 48C for 10 min. The supernatant was then incubated with 20 mg m L21 of
RNase A (2mL) and 20 mg m L21 of proteinase K (2mL) at 378C for 1 h, and then kept in
0.5 M NaCl (20mL) and isopropanol (120mL) at 2208C overnight, and centrifuged at
15,000g for 15 min. DNA was dissolved in TE buffer [10 mmol L21 Tris (pH 7.4),
10 mmol L21 DETA (pH 8.0)] and subjected to 2% agarose gel electrophoresis at 50 V for
40 min, and stained with ethidium bromide.
LDH Activity-based Cytotoxicity Assay
LDH activity was measured in both floating dead cells and viable adherent cells [22]. One
hundred mL ð1 £ 105 cells mL21Þ of a cell suspension were placed in the wells of 96-well
plates. They were then cultured in an incubator at 378C for 12 h. After treatment with
shikonin, floating cells were collected from the culture medium by centrifugation at 240g at
48C for 10 min. The LDH released in the culture medium was used as an index of necrotic
cell death (referred to as LDHdn). The pellets were lysed by 1% NP40 in RPMI 1640
(100mL) for 30 min at 378C, and centrifuged at 240g at 48C for 10 min. The supernatant was
transferred to other 96-well plates. The LDH content from the supernatant was used as an
index of apoptotic cell death (referred to as LDHda). The viable adherent cells were lysed by
1% NP40 in RPMI 1640 (100mL) at 378C for 30 min, and centrifuged at 240g at 48C for
10 min. The LDH present in the adherent viable cells was used as an index of viable cells
(LDHv). The percentage of apoptotic and necrotic cell death was calculated as follows:
% apoptosis ¼ LDHda=ðLDHdn þ LDHda þ LDHvÞ £ 100; and
% necrosis ¼ LDHdn=ðLDHdn þ LDHda þ LDHvÞ £ 100:
Caspases Activity Assay
HeLa cells (1 £ 106 cells) were incubated with or without shikonin. Harvested cells at various
time points were washed with PBS and centrifuged at 150g. Supernatant was aspirated off and
cell lysis buffer (provided) was added to an Eppendorf centrifuge at 0.5 mL per 1 £ 106 cells.
Cells in lysis buffer were incubated on ice for 10 min. Reaction buffer containing DDT (5mL),
of IETD-AFC (5mL) (or DEVD-AFC) substrate and H2O (380mL) was added to each aliquot
of cell lysate. The mixtures were then incubated at 378C for 1 h. The fluorescence of the
cleaved substrates was determined with a spectrofluorometer set at 400 nm (excitation
wavelength) and at 505 nm (emission wavelength). The unit of enzyme activity corresponds to
the activity that cleaves the respective substrate in 1 min per mg of protein at 378C.
Flow Cytometric Analysis
HeLa cells (1 £ 106 cells) were harvested and washed once in cold PBS. Cell pellets
were fixed in 70% ethanol and washed in cold PBS. Then the pellets were suspended










































in propidium iodide (PI) solution (1 mL) containing 50mg mL21 of PI, 0.1% (w/v) sodium
citrate, 0.1% (v/v) Triton X. Cell samples were incubated at 48C in the dark for at least
15 min, and analyzed by a FACScan flow cytometer (Becton Dickinson).
Cell Cycle Analysis
HeLa cells (1 £ 106 cells) were incubated with 2.5 mmol L21 thymidine (cell cycle blocker
from G1 to S phase) for 18 h, and collected by centrifugation at 100g for 5 min. The cells
were suspended in RPMI 1640 medium supplemented with 10% fetal bovine serum and
cultured for 15 h. They were then treated with 2.5 mmol L21 thymidine for 15 h again,
centrifuged at 100g for 5 min, washed with PBS, then stained with PI and analyzed by
fluorescence flow cytometry. The cells were further cultured with different concentrations of
shikonin for 12 h, then collected and centrifuged at 100g for 5 min, and analyzed by
fluorescence flow cytometry after staining with PI.
Western Blot Analysis
HeLa cells were harvested and lysed for 1 h on ice in lysis buffer [50 mmol L21 HEPES
(pH 7.4), 1% Triton X-100, sodium orthovanadate (2 mmol L21), sodium fluoride
(100 mmol L21), EDTA (1 mmol L21), EGTA (1 mmol L21), phenylmethanesulfonyl
fluoride (PMSF) (1 mmol L21)], supplemented with proteinase inhibitors aprotinin
(100mg mL21), leupeptin (10mg mL21), pepstatin (100mg mL21). The protein concen-
tration was determined by the Folin assay. The lysate was centrifuged at 16,000g at 48C for
10 min. Equal amounts of total protein were mixed in 2 £ loading buffer [50 mmol L21
Tris-HCl (pH 6.8), 2% SDS, 10% 2-mercaptoethanol, 10% glycerol, and 0.002%
bromphenol blue], boiled 5 min, and run on a 12% SDS–polyacrylamide gel electrophoresis.
Proteins were electrotransferred onto nitrocellulose membranes. After being blocked with
Tween 20–Tris-buffered saline [50 mmol L21 Tris–HCl (pH 7.5), 150 mmol L21 NaCl, and
0.02% Tween 20] containing 5% nonfat milk at room temperature, the membranes were
incubated for 2 h at room temperature with the primary antibodies at 1:200 dilution in
blotting buffer. After being washed three times, for 10 min each time, in Tris-buffered saline,
the membrane was incubated with a diluted horseradish peroxidase-labeled secondary
antibody (1:500) in blotting buffer at room temperature for 1 h. After a further three washes,
proteins were detected by chemiluminescence, according to the manufacturer’s instructions
(Bio-Rad, Hercules, CA).
Statistical Analysis
All data represent at least three independent experiments and are expressed as the
mean ^ SD unless otherwise indicated. Statistical comparisons were made by Student’s
t-test; significance was considered as p , 0:05:
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